<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>DSpace Общество:</title>
  <link rel="alternate" href="http://ir.librarynmu.com/handle/123456789/37" />
  <subtitle />
  <id>http://ir.librarynmu.com/handle/123456789/37</id>
  <updated>2026-04-28T15:49:41Z</updated>
  <dc:date>2026-04-28T15:49:41Z</dc:date>
  <entry>
    <title>Development of relevant quality criteria for a dietary supplement used in the management of decreased bone mineral density</title>
    <link rel="alternate" href="http://ir.librarynmu.com/handle/123456789/19406" />
    <author>
      <name>Golovchenko, O.</name>
    </author>
    <author>
      <name>Afanasenko, O.</name>
    </author>
    <author>
      <name>Nychyporuk, T.</name>
    </author>
    <id>http://ir.librarynmu.com/handle/123456789/19406</id>
    <updated>2026-04-17T11:44:49Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Название: Development of relevant quality criteria for a dietary supplement used in the management of decreased bone mineral density
Авторы: Golovchenko, O.; Afanasenko, O.; Nychyporuk, T.
Краткий осмотр (реферат): Decreased bone mineral density is a significant medical and social problem associated with an increased risk of fractures and deterioration in quality of life, particularly among elderly populations and postmenopausal women. Adequate intake of calcium is essential for bone formation; however, its effective absorption and incorporation into bone tissue depend on vitamin D and vitamin K. Vitamin D regulates intestinal calcium absorption, while vitamin K is involved in the activation of osteocalcin, a key protein responsible for calcium binding in bone matrix.</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>A modern approach to developing specifications for a generic drug used to treat aromatic amino acid metabolism disorders</title>
    <link rel="alternate" href="http://ir.librarynmu.com/handle/123456789/19405" />
    <author>
      <name>Afanasenko, O.</name>
    </author>
    <author>
      <name>Nesterenko. V.</name>
    </author>
    <id>http://ir.librarynmu.com/handle/123456789/19405</id>
    <updated>2026-04-17T11:42:36Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Название: A modern approach to developing specifications for a generic drug used to treat aromatic amino acid metabolism disorders
Авторы: Afanasenko, O.; Nesterenko. V.
Краткий осмотр (реферат): Inherited disorders of aromatic amino acid metabolism, particularly hereditary tyrosinemia type I, are severe genetic diseases requiring lifelong dietary and pharmacological management. Specialized amino acid mixtures free of tyrosine represent the cornerstone of therapy, as they provide essential amino acids while preventing the accumulation of toxic metabolites.</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Formulation of modern requirements for the quality of dietary supplements containing theobromine</title>
    <link rel="alternate" href="http://ir.librarynmu.com/handle/123456789/19404" />
    <author>
      <name>Syrotchuk, O.</name>
    </author>
    <author>
      <name>Afanasenko, O.</name>
    </author>
    <author>
      <name>Nasylenko, I.</name>
    </author>
    <id>http://ir.librarynmu.com/handle/123456789/19404</id>
    <updated>2026-04-17T11:39:58Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Название: Formulation of modern requirements for the quality of dietary supplements containing theobromine
Авторы: Syrotchuk, O.; Afanasenko, O.; Nasylenko, I.
Краткий осмотр (реферат): The increasing consumption of dietary supplements containing biologically active substances has raised significant concerns regarding their quality, safety, and regulatory control. Theobromine, a naturally occurring methylxanthine widely used in functional and stimulant dietary supplements, exhibits pharmacological activity affecting the central nervous, cardiovascular, and metabolic systems. Despite its growing application, unified and scientifically substantiated quality requirements for dietary supplements containing theobromine remain insufficiently developed, particularly within the Ukrainian regulatory framework. This creates potential risks related to inconsistent dosing, inaccurate labeling, and inadequate quality control. Therefore, the development of modern quality requirements and control approaches for dietary supplements containing theobromine is highly relevant in the context of harmonization of national regulations with European standards and ensuring consumer safety.</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Development of modern quality requirements for a dietary supplement containing silymarin</title>
    <link rel="alternate" href="http://ir.librarynmu.com/handle/123456789/19403" />
    <author>
      <name>Afanasenko, O.</name>
    </author>
    <author>
      <name>Vysotska, D.</name>
    </author>
    <id>http://ir.librarynmu.com/handle/123456789/19403</id>
    <updated>2026-04-17T11:36:47Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Название: Development of modern quality requirements for a dietary supplement containing silymarin
Авторы: Afanasenko, O.; Vysotska, D.
Краткий осмотр (реферат): Silymarin is a complex of biologically active flavonolignans derived from Silybum marianum, widely used in dietary supplements intended to support liver function and detoxification processes. Due to its antioxidant, anti-&#xD;
inflammatory, and membrane-stabilizing properties, silymarin-containing products are in high demand and are extensively represented on the pharmaceutical and consumer markets. However, dietary supplements in Ukraine are regulated as food products rather than medicinal products, which results in limited requirements for standardization, identification, and quantitative determination of active substances.</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
</feed>

